Healthy infants receiving a profylactic vaccine to prevent measles infection
Conditions
Brief summary
Measles specific virus neutralising antibody concentrations 4 weeks post MMR-0 immunisation
Detailed description
Measles specific maternal antibody concentrations prior to MMR-0 immunisation., Measles specific virus neutralising antibody concentrations prior to, 4 weeks post and 1 year post MMR-1 immunisation in MMR-0 immunised children and a control group., Assess MMR vaccination induced reactogenicity after MMR‐0 and MMR‐1 as an indication for vaccine responsiveness., Serum binding IgG antibody concentrations against measles, mumps and rubella prior to and 4 weeks post MMR-0 and prior to, 4 weeks post and 1 year post MMR-1 in MMR-0 immunised children and a control group.
Interventions
Sponsors
Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measles specific virus neutralising antibody concentrations 4 weeks post MMR-0 immunisation | — |
Secondary
| Measure | Time frame |
|---|---|
| Measles specific maternal antibody concentrations prior to MMR-0 immunisation., Measles specific virus neutralising antibody concentrations prior to, 4 weeks post and 1 year post MMR-1 immunisation in MMR-0 immunised children and a control group., Assess MMR vaccination induced reactogenicity after MMR‐0 and MMR‐1 as an indication for vaccine responsiveness., Serum binding IgG antibody concentrations against measles, mumps and rubella prior to and 4 weeks post MMR-0 and prior to, 4 weeks post and 1 year post MMR-1 in MMR-0 immunised children and a control group. | — |
Countries
Netherlands
Outcome results
None listed